Patents by Inventor Kanagasabai Panchalingam

Kanagasabai Panchalingam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8894973
    Abstract: The invention is a method for the differential diagnosis of chronic schizophrenia or chronic alcoholism, by imaging the brain of a subject to detect any or all of the markers phosphocreatine (PCr), N-acetyl aspartate divided by the total creatine signal (NA/Crt), and synaptic phosphodiester (sPDE), and determining any increase or decrease in the presence of such markers compared to normal levels in specified anatomic areas of the brain. The output of such a method, resulting from such imaging, is presented to be viewed by a diagnostician in order to support the differential diagnosis based on the data output.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: November 25, 2014
    Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam
  • Patent number: 8329142
    Abstract: Compounds, compositions and methods for the detection and diagnosis of Parkinson's disease. Derivative lycerophosphocholine (GPC) compounds are used as a detection and diagnostic aid to measure progression of Parkinson's disease by detecting GPC binding to ?-synuclein. Derivative CPG compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging (MRI) and/or positron emission tomography (PET) applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the detection, diagnosis and assessment of the progression of Parkinson's disease may be achieved.
    Type: Grant
    Filed: July 23, 2008
    Date of Patent: December 11, 2012
    Inventors: Jay W. Pettegrew, Richard J. McClure, Kanagasabai Panchalingam
  • Patent number: 7815894
    Abstract: Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the ?-turn of beta amyloid (A?) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: October 19, 2010
    Inventors: Jay W. Pettegrew, Richard J. McClure, Kanagasabai Panchalingam, Billy W. Day
  • Patent number: 7700074
    Abstract: Chronic alcoholism is a diverse and heterogeneous disorder that can be dichotomized into cognitively intact and cognitively impaired subgroups. At a molecular level, ethanol has been shown to have both acute and chronic effects on: Membrane biophysical properties, Membrane composition and metabolism, Protein phosphorylation, Lipid metabolic signaling, Lipoprotein transport of cholesterol. Actual molecular underpinnings are determined for cognitive impairment seen in some chronic alcoholism subjects including molecular/metabolic alterations of phospholipid and ganglioside metabolisms.
    Type: Grant
    Filed: August 23, 2005
    Date of Patent: April 20, 2010
    Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam
  • Publication number: 20100010336
    Abstract: A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.
    Type: Application
    Filed: July 23, 2009
    Publication date: January 14, 2010
    Inventors: Jay W. PETTEGREW, Kanagasabai Panchalingam
  • Patent number: 7632662
    Abstract: Carnitines are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to produce longer chain fatty acid esters of carnitines such as polyunsaturated fatty acid esters including eicosapentaenoyl-L-carnitine and/or docosahexaenyl-L-carnitine in germinating plant seeds. The resulting products from the plant seeds are used as a natural nutritional source of powerful human antioxidants.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: December 15, 2009
    Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam, Richard J. McClure
  • Publication number: 20090069423
    Abstract: Carnitines are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to produce longer chain fatty acid esters of carnitines such as polyunsaturated fatty acid esters including eicosapentaenoyl-L-carnitine and/or docosahexaenyl-L-carnitine in germinating plant seeds. The resulting products from the plant seeds are used as a natural nutritional source of powerful human antioxidants.
    Type: Application
    Filed: July 31, 2008
    Publication date: March 12, 2009
    Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam, Richard J. McClure
  • Publication number: 20080292557
    Abstract: Compounds, compositions and methods for the detection and diagnosis of Parkinson's disease. Derivative lycerophosphocholine (GPC) compounds are used as a detection and diagnostic aid to measure progression of Parkinson's disease by detecting GPC binding to ?-synuclein. Derivative CPG compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging (MRI) and/or positron emission tomography (PET) applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the detection, diagnosis and assessment of the progression of Parkinson's disease may be achieved.
    Type: Application
    Filed: July 23, 2008
    Publication date: November 27, 2008
    Inventors: Jay W. Pettegrew, Richard J. McClure, Kanagasabai Panchalingam
  • Patent number: 7407778
    Abstract: Acetyl-L-carnitine (ALCAR) and L-carntine (LCAR) are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to enhance ALCAR and LCAR formation in germinating plant seeds. Metabolic fluxes are manipulated by germination in bioreactors to increase oxygen availability as well as provide an aseptic environment to alter carbohydrate consumption and feedback repress gluconeogenesis. Large shifts in sunflower seed fatty acid, phospholipid and high-energy metabolism change the germination environment and these metabolic changes lead to an approximate 1000-fold increase in natural LCAR and ALCAR production by the seeds. The resulting LCAR and ALCAR products from the seeds are used for treating mental health disorders including Alzheimer's disease, geriatric depression, non-geriatric depression and schizophrenia.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: August 5, 2008
    Inventors: Jay W. Pettegrew, Samuel Gershon, Kanagasabai Panchalingam
  • Publication number: 20060292547
    Abstract: Chronic alcoholism is a diverse and heterogeneous disorder that can be dichotomized into cognitively intact and cognitively impaired subgroups. At a molecular level, ethanol has been shown to have both acute and chronic effects on: Membrane biophysical properties, Membrane composition and metabolism, Protein phosphorylation, Lipid metabolic signaling, Lipoprotein transport of cholesterol. Actual molecular underpinnings are determined for cognitive impairment seen in some chronic alcoholism subjects including molecular/metabolic alterations of phospholipid and ganglioside metabolisms.
    Type: Application
    Filed: August 23, 2005
    Publication date: December 28, 2006
    Inventors: Jay Pettegrew, Kanagasabai Panchalingam
  • Publication number: 20060257842
    Abstract: The cryopreservation media utilizes naturally occurring endogenous molecules and their chemical derivatives which act as osmotically active cryopreservative agents as well as molecules which insert into and protect specific regions of cellular membranes, lead to membrane repair, maintain normal cellular levels of energy metabolites, and act as antioxidants. Cryoperserved cells can be returned to a pre- cryopreservation state without damaging the cells resulting in a very high survival rate.
    Type: Application
    Filed: April 21, 2006
    Publication date: November 16, 2006
    Inventors: Jay Pettegrew, Thomas Glonek, Richard McClure, Kanagasabai Panchalingam
  • Publication number: 20060088614
    Abstract: Acetyl-L-carnitine (ALCAR) and L-carntine (LCAR) are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to enhance ALCAR and LCAR formation in germinating plant seeds. Metabolic fluxes are manipulated by germination in bioreactors to increase oxygen availability as well as provide an aseptic environment to alter carbohydrate consumption and feedback repress gluconeogenesis. Large shifts in sunflower seed fatty acid, phospholipid and high-energy metabolism change the germination environment and these metabolic changes lead to an approximate 1000-fold increase in natural LCAR and ALCAR production by the seeds. The resulting LCAR and ALCAR products from the seeds are used for treating mental health disorders including Alzheimer's disease, geriatric depression, non-geriatric depression and schizophrenia.
    Type: Application
    Filed: August 5, 2005
    Publication date: April 27, 2006
    Inventors: Jay Pettegrew, Samuel Gershon, Kanagasabai Panchalingam
  • Publication number: 20040241090
    Abstract: Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the &bgr;-turn of beta amyloid (A&bgr;) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.
    Type: Application
    Filed: May 27, 2004
    Publication date: December 2, 2004
    Inventors: Jay W. Pettegrew, Richard J. McClure, Kanagasabai Panchalingam, Billy W. Day